Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.78 |
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29452862 | 1.00 | LMNA (0.78) | LMNAALDH1A1MAPTMAPK1HSD17B10 | |
| SCHEMBL31721163 | 0.88 | LMNA (1.00) | LMNAALDH1A1MAPTMAPK1HSD17B10 | |
| SCHEMBL2360729 | 0.88 | LMNA (1.00) | LMNAALDH1A1MAPTMAPK1HSD17B10 | |
| SCHEMBL4156981 | 0.84 | LMNA (0.94) | LMNAALDH1A1MAPTMAPK1HSD17B10 | |
| SCHEMBL16433484 | 0.81 | LMNA (0.52) | LMNAALDH1A1MAPTMAPK1HSD17B10 | |
| SCHEMBL6069754 | 0.81 | MAPT (0.51) | LMNAALDH1A1MAPTMAPK1HSD17B10 | |
| SCHEMBL4021839 | 0.78 | HSD17B10 (1.00) | LMNAALDH1A1MAPTMAPK1HSD17B10 | |
| SCHEMBL29666273 | 0.78 | HSD17B10 (1.00) | LMNAALDH1A1MAPTMAPK1HSD17B10 | |
| SCHEMBL6449055 | 0.78 | HSD17B10 (0.59) | LMNAALDH1A1MAPTMAPK1HSD17B10 | |
| SCHEMBL4152464 | 0.78 | MAPT (0.56) | LMNAALDH1A1MAPTMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409680-B | PPAR agonists and uses thereof | 上海怡立舍生物技术有限公司 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023121238-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121238-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | disclosed |
| US-11458121-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-10-04 | — | — | US | disclosed |
| CN-108250058-B | PPAR agonists and their use in the treatment of Alzheimer's disease and other diseases | 上海怡立舍生物技术有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| WO-2019141229-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | 上海怡立舍生物技术有限公司 | 2019-07-25 | — | — | WO | disclosed |
| WO-2019005841-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005841-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| EP-1658068-B1 | NOVEL CYCLOALKYL[B] CONDENSED INDOLES | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| EP-1817026-A2 | HCV INHIBITORS | SmithKline Beecham Corporation (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060281804-A1 | Novel cycloalkyl'b! condensed indoles | SMITHKLINE BEECHAM CORPORATION | 2006-12-14 | — | — | US | disclosed |
| WO-2006121466-A2 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-1658068-A1 | NOVEL CYCLOALKYL'B! CONDENSED INDOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005023245-A1 | NOVEL CYCLOALKYL’B! CONDENSED INDOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11458121-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC10A1, SLC47A1 | LMNA 4360/4885ALDH1A1 617/4885MAPT 4110/4885 |
| US-20090170923-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | LMNA 4279/4885ALDH1A1 1558/4885MAPT 1187/4885 |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | VEGFA, FLT4, KDR | LMNA 4109/4885ALDH1A1 2199/4885MAPT 2774/4885 |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | LMNA 4360/4885ALDH1A1 617/4885MAPT 4110/4885 |
| US-20060281804-A1 | Novel cycloalkyl'b! condensed indoles | BCCIP, TP53, TOP2B | LMNA 2198/4885ALDH1A1 3045/4885MAPT 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.